RELMADA THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
RELMADA THERAPEUTICS, INC. (RLMD) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 2.15% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-27
- RELMADA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 2.15%, a 26.47% increase from fiscal 2023.
- RELMADA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 1.70%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | 2.15% 10-K · filed 2025-03-27 |
| 2023-12-31 | 1.70% 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |